Molecular Mechanism Regulating Regeneration of Spinal Nerves Identified
|
By LabMedica International staff writers Posted on 29 Mar 2016 |

Image: A confocal micrograph of the lesion core following spinal cord injury. Nuclear EdU (red) shows the presence of newly differentiated cells which produce Schwann cell myelin (green). These peripheral-like Schwann cells remyelinate central axons in the injured spinal cord and are important for spontaneous repair and functional recovery after spinal cord injury (Photo courtesy of King\'s College London).
The protein neuregulin-1 was found to regulate the repair mechanism that attempts to restore lost myelin following spinal cord injury.
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Latest BioResearch News
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more








